Merus N.V. (MRUS)
| Previous close | 25.90 |
| Open | 25.44 |
| Bid | 24.03 x 800 |
| Ask | 26.00 x 1100 |
| Day's range | 24.50 - 26.73 |
| 52-week range | 16.14 - 33.09 |
| Volume | |
| Avg. volume | 251,787 |
| Market cap | 1.131B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Merus Presents Updated Analysis of Zenocutuzumab, Trastuzumab, and Vinorelbine in Patients with HER2+ Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium
- The primary endpoint of Clinical Benefit Rate at 24 weeks with the triplet combination was met - The triplet combination showed clinically meaningful activity after 3 lines of anti-HER2 therapies including T-DM1 - Validates the potential of zenocutuzumab in additional indications outside NRG1 fusions UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing in
- Globe Newswire
Merus Presents Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today released clinical data on MCLA-145 from the phase 1 trial in patients with solid tumors at the ESMO Immuno-Oncology Congress 2021 being held virtually. “We are encouraged by the progress we are making with MCLA-145,” said
- Globe Newswire
Merus Announces Poster Presentation on Clinical Data on MCLA-145 at the ESMO Immuno-Oncology Congress 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of the abstract highlighting interim data, as of a July 14, 2021 cutoff, from the phase 1/2 trial of bispecific antibody MCLA-145 in patients with solid tumors. The e-poster will be presented at
